Hepion Pharmaceuticals, Inc.
HEPA evidence brief
What we can confirm
- BioSniper Score:
- 9.6 / 10
- Market Cap:
- $6.4M
What it means
What to watch
Prepared research question
What matters most for HEPA—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper AI · HEPA
Hepion Pharmaceuticals, Inc. (HEPA) is a biopharmaceutical company that historically focused on developing rencofilstat, a cyclophilin inhibitor for liver diseases, but has since begun wind-down activities and is now pursuing strategic alternatives with limited financial resources.
Key risk: Wind-down of core program
BioSniper Score
Based on 2 of 6 signals
Limited data coverage
Market Cap
$6.4M
Cash Runway
—
Lead Asset
—
Next Catalyst
—
Financial data as of Jun 30, 2026.
Tracking 3 clinical trials for Hepion Pharmaceuticals, Inc..
Hepion Pharmaceuticals, Inc. (HEPA) is a biopharmaceutical company that historically focused on developing rencofilstat, a cyclophilin inhibitor for liver diseases, but has since begun wind-down activities and is now pursuing strategic alternatives with limited financial resources.
- Hepion's lead molecule, rencofilstat (formerly CRV431), is a cyclophilin inhibitor that was being developed for liver diseases including NASH and HCC [sec_mda · as of 2025-11-12].
- The company announced on April 19, 2024, that it had begun wind-down activities [sec_mda · as of 2025-11-12].
- As of 2026-06-30, Hepion reported a net loss of -$1.2M and shareholders' equity of $1.3M [sec].
- Hepion's Phase 2a study (ALTITUDE-NASH) met its primary endpoint in May 2023, showing improved liver function and tolerability [sec_mda · as of 2024-11-14].
- The company is now focused on a strategic alternatives strategy, expending resources on acquired assets [sec_mda · as of 2026-03-12].
What works
- Rencofilstat completed Phase 1 and Phase 2 trials, with the Phase 2a ALTITUDE-NASH study meeting its primary endpoint by demonstrating improved liver function and tolerability [sec_mda · as of 2024-11-14].
- The company has a defined strategic alternatives strategy, indicating active pursuit of new opportunities [sec_mda · as of 2026-03-12].
What to weigh
- Hepion has begun wind-down activities as of April 2024, signaling a cessation of its primary development program [sec_mda · as of 2025-11-12].
- The company reported a net loss of -$1.2M and minimal shareholders' equity of $1.3M as of 2026-06-30, indicating very limited financial resources [sec].
- Future capital requirements are uncertain and depend on many factors, including the scope and costs of developing any new product candidates [sec_mda · as of 2026-03-12].
From the filings
Quoted directly from source documents.
Hepion began wind-down activities in April 2024.
“On April 19, 2024, we announced that we have begun wind-down activities in”
SEC MD&A · November 12, 2025
Rencofilstat is a cyclophilin inhibitor developed for liver disease.
“Our cyclophilin inhibitor, rencofilstat (formerly CRV431), was being developed to offer benefits to address multiple complex pathologies related to the progression of liver disease.”
SEC MD&A · November 12, 2025
Phase 2a ALTITUDE-NASH study met its primary endpoint.
“In May 2023, we announced that our Phase 2a study ("ALTITUDE-NASH") met its primary endpoint by demonstrating improved liver function and was well tolerated after four months of treatment with once daily oral rencofilstat administered to NASH subjects with stage 3 or greater fibrosis.”
SEC MD&A · November 14, 2024
Risks & what to watch (3)›
Key risks
- Wind-down of core program — Hepion has begun wind-down activities, ceasing development of its lead molecule rencofilstat [sec_mda · as of 2025-11-12].
- Minimal financial resources — As of 2026-06-30, Hepion has only $1.3M in shareholders' equity and a net loss of -$1.2M [sec].
- Uncertain strategic alternatives — Future capital needs depend on many factors, and the outcome of the strategic alternatives strategy is unknown [sec_mda · as of 2026-03-12].
What to watch
- Progress and outcomes of Hepion's strategic alternatives strategy, including any new asset acquisitions or partnerships [sec_mda · as of 2026-03-12].
- Any further financial disclosures or capital raises given the company's minimal equity position [sec].
- Potential regulatory or clinical developments if Hepion resumes development of rencofilstat or other candidates [sec_mda · as of 2025-11-12].
Sources: Catalysts · SEC MD&A · Generated September 29, 2026 · How we verify sources →
Run Hepion Pharmaceuticals, Inc. through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available Hepion Pharmaceuticals, Inc. facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Evidence & data
Score breakdownBased on 2 of 6 signals · derived from public data
Pipeline inputs are unavailable for this score. It uses only the available signals shown below.
Cash runway data unavailable
D/E 0.51 · 0% dilution
No tracked pipeline phase
No tracked pipeline candidates
No upcoming catalysts tracked
11 buys · 0 sells (180d)
Regulatory
Financials
Governance
Frequently asked questions
What is the AI investment thesis for Hepion Pharmaceuticals, Inc.?
Hepion Pharmaceuticals, Inc. (HEPA) is a biopharmaceutical company that historically focused on developing rencofilstat, a cyclophilin inhibitor for liver diseases, but has since begun wind-down activities and is now pursuing strategic alternatives with limited financial resources.
Who is the CEO of Hepion Pharmaceuticals, Inc.?
Mr. Gary S. Stetz CPA is the chief executive officer of Hepion Pharmaceuticals, Inc. (HEPA).
Where is Hepion Pharmaceuticals, Inc. headquartered?
Hepion Pharmaceuticals, Inc. (HEPA) is headquartered in Morristown, NJ, United States.
What therapeutic areas does Hepion Pharmaceuticals, Inc. focus on?
Hepion Pharmaceuticals, Inc. develops therapies across Cardiovascular.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.